Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.41 |
| ▸ | MERTK | Q12866 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 7/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710536 | 0.81 | ACVRL1 (0.38) | ACVRL1RETKDRPIK3CD | |
| SCHEMBL15826967 | 0.80 | AXL (0.54) | AXLMERTKTYRO3ACVRL1RET | |
| SCHEMBL19701790 | 0.77 | PIK3CD (0.54) | AXLMERTKTYRO3ACVRL1PIK3CD | |
| SCHEMBL64684 | 0.77 | ACVRL1 (0.51) | AXLMERTKALDH1A1TYRO3ACVRL1 | |
| SCHEMBL19701786 | 0.77 | PIK3CD (0.47) | AXLMERTKALDH1A1TYRO3ACVRL1 | |
| SCHEMBL12365553 | 0.76 | ALDH1A1 (0.43) | AXLMERTKALDH1A1TYRO3ACVRL1 | |
| SCHEMBL66503 | 0.76 | ALDH1A1 (0.43) | AXLMERTKALDH1A1TYRO3ACVRL1 | |
| SCHEMBL19701791 | 0.76 | ACVRL1 (0.44) | AXLMERTKTYRO3ACVRL1PIK3CD | |
| SCHEMBL64680 | 0.75 | ALDH1A1 (0.42) | AXLMERTKALDH1A1TYRO3ACVRL1 | |
| SCHEMBL19701779 | 0.74 | ACVRL1 (0.38) | AXLMERTKALDH1A1TYRO3ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024091370-A1 | 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | AXL 1201/4885MERTK 2883/4885ALDH1A1 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.